This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Health Discovery Corporation (OTCBB: HDVY), the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment, today debuts its popular MelApp mobile app for Android™ devices. Now, health-conscious consumers can easily learn about melanoma and identify areas on their skin which may need attention from a specialist, anytime, anywhere with their iPhone, iPod Touch and iPad, as well as Android smartphone.
First launched this summer for iPhone, MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. The app was validated using an image database licensed from Johns Hopkins University Medical Center and uses a device’s camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. In addition, MelApp can use the smartphone’s GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical diagnosis and treatment.
“Being currently used in nearly 50 countries, and having been named one of the ‘Top 10 Apps That Could Save Your Life’
in a recent issue of Parade Magazine, MelApp has become a worldwide success,” stated Stephen D. Barnhill, M.D. Chairman and CEO of Health Discovery Corporation. “With the launch of MelApp for Android our goal was to extend the availability of this easy to use, inexpensive and potentially life-saving app to the more than 46 percent of the smart phone market that use Android devices, according to Nielsen.”
Now available for iPhone, iPod touch, and iPad, as well as for Android, MelApp is available for download at a special limited time price of $1.99 at the following app marketplaces:
This version of MelApp for Android has been optimized for the Droid X. For support and technical inquiries, contact
Physicians who diagnose and treat melanoma can become a subscribing member of HDC’s physician referral network by contacting
About MelApp & Health Discovery Corporation
MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze the uploaded image. MelApp was validated using an image database licensed from Johns Hopkins University Medical Center and uses a device’s camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. The app can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up. MelApp by Health Discovery Corporation is available at a special limited time introductory price of $1.99. For more complete details, visit
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.